Advancing Methods for Safe, Noninvasive, Real Time Assessment of Placenta Development and Function Across Pregnancy (R01 Clinical Trial Not Allowed)
ID: 343745Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/343745

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-237.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity for advancing methods to safely and noninvasively assess placenta development and function throughout pregnancy, specifically through the R01 grant mechanism. This initiative aims to support the Human Placenta Project (HPP) by encouraging the development of innovative technologies and biomarkers that can monitor placental health in real time, with a focus on safety, clinical feasibility, and multidisciplinary collaboration. Eligible applicants include a wide range of organizations, from higher education institutions to foreign entities, with applications due by November 5, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-237.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-22-237-Full-Announcement.html
    PAR-22-237.html
    The Department of Health and Human Services, through the National Institutes of Health, has issued a funding opportunity announcement (FOA) for advancing noninvasive methods to assess placental development and function during pregnancy. The initiative aims to facilitate the Human Placenta Project (HPP), which focuses on developing innovative technologies and biomarkers to monitor placental health in real time. The FOA invites applications for R01 grants to improve assessment tools applicable throughout pregnancy, especially during early gestation. Key priorities include safety, clinical feasibility, and the integration of multidisciplinary expertise, including the involvement of obstetric clinicians and biostatisticians. Applicants are encouraged to pursue novel technologies for real-time analyses and share data collaboratively. Eligible organizations range from higher education institutions to foreign entities, with awards contingent upon NIH appropriations. The review process will assess applications based on significance, innovation, approach, and investigator qualifications. This funding opportunity reflects NIH's commitment to enhancing maternal-fetal health through advanced research on placental function and dysfunction during pregnancy.
    Similar Opportunities
    Advancing Methods for Safe, Noninvasive, Real Time Assessment of Placenta Development and Function Across Pregnancy (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Methods for Safe, Noninvasive, Real Time Assessment of Placenta Development and Function Across Pregnancy" under the R21 grant mechanism. This initiative aims to support the development and clinical validation of innovative, non-invasive methods to assess placental health throughout pregnancy, addressing critical issues such as preeclampsia and fetal growth restrictions. The funding, capped at $275,000 over a two-year period, is open to a diverse range of eligible applicants, including higher education institutions, nonprofit organizations, and tribal governments, with a submission deadline of November 16, 2024. Interested parties can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional)" aimed at investigating the interactions between HIV, antiretroviral therapy (ART), and substance use during pregnancy. This initiative seeks to enhance understanding of placental health and its implications for maternal and fetal outcomes, particularly focusing on the pathophysiology of placental abnormalities in the context of substance misuse. The NIH plans to allocate up to $2 million for fiscal year 2025 to support 2-5 research project grants, with applications opening on October 15, 2024, and a submission deadline of November 15, 2024. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Understanding the Impact of Healthcare System and Clinician Factors on Disparities in Maternal Morbidity and Mortality (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Understanding the Impact of Healthcare System and Clinician Factors on Disparities in Maternal Morbidity and Mortality" (NOFO PAR-24-059). This initiative aims to support multidisciplinary research focused on addressing the high rates of maternal morbidity and mortality in the United States, particularly among racial and ethnic minorities, socioeconomically disadvantaged groups, and underserved rural populations. The program encourages innovative intervention studies that evaluate healthcare factors affecting maternal health, with the goal of reducing disparities and improving outcomes across the continuum of care from prenatal to postpartum. Eligible applicants include a range of organizations, and awards can last up to five years, with budgets tailored to project needs. Interested parties can find more information and apply by visiting the NIH grants website, with the application deadline set for January 7, 2027.
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)" aimed at advancing research in drug safety and effectiveness for pregnant individuals, lactating persons, and children. This initiative seeks to support innovative projects that develop novel methodologies, enhance understanding of drug mechanisms, and promote precision medicine to address significant unmet medical needs in maternal and pediatric health. Eligible applicants include a wide range of institutions, such as historically black colleges and universities, tribal colleges, and various nonprofit organizations, with funding available up to $275,000 over a two-year period. Interested parties should note that applications are accepted until December 16, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional)" aimed at supporting the development of innovative Multipurpose Prevention Technologies (MPTs) that prevent HIV, sexually transmitted infections (STIs), and pregnancy. The initiative encourages applications that focus on both event-driven and long-acting MPTs, integrating user-desired features to enhance adoption and adherence, while also promoting biobehavioral research alongside pharmacokinetic and pharmacodynamic studies. This funding opportunity is open to a wide range of eligible applicants, including higher education institutions, nonprofits, and various community organizations, with applications due by December 7, 2024. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-180.html.
    Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research into the mechanisms underlying structural birth defects. This grant encourages applicants to utilize animal models alongside human translational and clinical approaches, focusing on genetic, epigenetic, and environmental factors that contribute to these conditions. With over 120,000 infants affected annually in the U.S., this research is critical for public health, and projects may receive funding of up to $499,999 per year for a maximum of five years. Interested applicants must submit their proposals by September 7, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details at https://grants.nih.gov/grants/guide/pa-files/PAR-22-215.html.
    The Road to Prevention of Stillbirth Clinical Research Centers (UG1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Road to Prevention of Stillbirth – Clinical Research Centers" funding opportunity, aimed at establishing Research Centers within the Stillbirth Research Consortium. This initiative focuses on reducing the incidence of stillbirth in vulnerable populations through interdisciplinary research, with key objectives including the development of clinical tools, understanding mechanisms contributing to stillbirth, and enhancing maternal-fetal communication. The program emphasizes collaboration among diverse research teams and requires a Plan for Enhancing Diverse Perspectives and a Plan for Inclusion of People with Lived Experience. An estimated $4.3 million in direct costs is available, with awards expected to support 3-5 projects, each with a maximum budget of $860,000 annually for up to 5 years. Interested applicants must submit preliminary letters of intent and adhere to comprehensive submission guidelines by the closing date of November 1, 2024. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns," aimed at developing novel screening techniques and therapeutic interventions for potentially fatal or disabling conditions identified through newborn screening. This initiative encourages diverse scientific research focused on improving screening technologies, therapeutic interventions, and preclinical testing, particularly for "high priority" genetic conditions that are not currently recommended for screening but could benefit from early identification and treatment. Eligible applicants include a wide range of organizations, such as educational institutions, community-based organizations, and tribal governments, with applications due by November 5, 2024. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-21-353.html.
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)" aimed at advancing precision medicine for pregnant individuals, lactating persons, and children. This grant seeks to support translational and clinical research that develops novel tools and methodologies to enhance the understanding of drug action mechanisms and improve the safety and effectiveness of therapeutics for these populations. The initiative is crucial for addressing critical gaps in healthcare for vulnerable groups, with a focus on discovering safer medications and utilizing innovative approaches such as machine learning for precision dosing. Interested applicants can find more information and submit proposals by May 7, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R03 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns," aimed at encouraging research into novel screening methods and therapeutic interventions for serious genetic and congenital conditions identified through newborn screening. This initiative, under the R03 Small Grant Program, supports small-scale projects lasting up to two years with a budget of up to $50,000 per year, focusing on developing robust screening technologies to enhance early detection and treatment of disorders, thereby minimizing long-term health consequences. The program is particularly important for addressing high-priority conditions where screening is not currently recommended, and it emphasizes inclusivity in research by inviting applications from a diverse range of organizations, including higher education institutions and community-based organizations. Interested applicants should note that the application deadline is November 16, 2024, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.